Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2020

View Archived Issues

'Superkiller' is broad-spectrum antiviral target

CDK4/6 inhibitors affect transcriptional landscape

PTC Therapeutics initiates phase I study of PTC-518

Intermittent schedule of CH-5126766 shows activity across several RAS-RAF-driven cancers

Peptide-conjugated ReNcell-derived EVs: a new therapeutic approach for pulmonary hypertension

Phase I data presented for AMG-890 in patients with elevated plasma Lp(a)

Neuro-drug repurposed to treat MDR Gram-negative sepsis

Pionyr initiates phase I study of its immuno-oncology candidate, PY-314

Phase II/III CAPELLA study of lenacapavir meets primary endpoint

First-in-human biomarker analysis for JNJ-55920839 in SLE

University of Kansas, Fox Chase Cancer Center describe anti-CTLA-4 antibodies

Yeda Research & Development patents polypeptides comprising propeptides of human lysyl oxidase

PROTACs targeting CDK12 and/or a CDK9 synthesized at the Dana-Farber Cancer Institute

JAK inhibitor prodrugs discovered at Theravance Biopharma

Beta Pharma identifies new HCV NS5A inhibitors

Supemtek quadrivalent recombinant influenza vaccine approved in E.U.

Preliminary phase I data for the half-life extended BiTE immune therapy, AMG-757

Bioventus receives IND clearance to study PTP-001 for knee osteoarthritis

FDA clears initiation of phase I trial of anti-LILRB2/ILT4 antibody JTX-8064

Synergy seen for DA-1241 with DPP4 inhibitor for the treatment of NASH

BioVersys initiates phase I testing of BV-100 for carbapenem-resistant A. baumannii infections

Interim data from phase Ib/IIa study of VBI-2601 for chronic hepatitis B

Genoscience completes phase Ib study of GNS-561 in primary and secondary liver cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...